TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7719087

Group type: EXPERIMENTAL
Intervention: Combined therapy (laparoscopy + TCM including low dose Methotrexate, modified Huo‐Luo‐Xiao‐Ling Dan, Ding‐Tong paste, Zi‐Gong pill)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (using TCM only)
Number of subjects: 44
Study: 2563046

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1846
Study: 4832320

Group type: EXPERIMENTAL
Intervention: Copper 7 IUCD
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dalkon shield IUCD
Number of subjects: 121
Study: 31056272

Group type: EXPERIMENTAL
Intervention: Supercritical fluid chromatography (SFC) method for quantifying flupirtine and its metabolites (4‐fluorohippuric acid and D‐13223)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SFC method applied to clinical samples after single intravenous (100 mg), single oral (100 mg), and repeated oral administration (400 mg)
Number of subjects: 0
Study: 27922025

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 3303

Group type: COMPARATOR
Intervention: Traditional Air Insufflation (AI)
Number of subjects: 3303
Study: 26366072

Group type: EXPERIMENTAL
Intervention: Tele monitoring (TM) with video consultations
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 281
Study: 24024587

Group type: EXPERIMENTAL
Intervention: SDM training for general practitioners (GPs)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Usual care without prior SDM training for GPs
Number of subjects: 1120
Study: 22462236

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Breast milk only (Control)
Number of subjects: 10
Study: 19346975

Group type: EXPERIMENTAL
Intervention: Muscle Armor (MA) supplementation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous placebo (CON)
Number of subjects: 17
Study: 16762702

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg preoperatively, 200 mg postoperatively)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 200
Study: 15589355

Group type: EXPERIMENTAL
Intervention: Eight deep breaths (8DB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tidal volume breathing (3TV)
Number of subjects: 20
Study: 15328782

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg at 21:30, followed by 100 mg at 03:00 and 05:00)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10718163

Group type: EXPERIMENTAL
Intervention: Lamotrigine 125 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lamotrigine 250 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8883530

Group type: EXPERIMENTAL
Intervention: Iodixanol at 320 mg I/kg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 46
Study: 1547766

Group type: EXPERIMENTAL
Intervention: Intrarectal diazepam (DZP) 20 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intrarectal diazepam (DZP) 30 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intrarectal diazepam (DZP)
Number of subjects: 39
Study: 2863922

Group type: EXPERIMENTAL
Intervention: Combination of 0.5 mg fluphenazine and 10 mg nortriptyline (Motival)
Number of subjects: 233

Group type: COMPARATOR
Intervention: 0.5 mg fluphenazine
Number of subjects: 233

Group type: COMPARATOR
Intervention: 10 mg nortriptyline
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 3341247

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30051188

Group type: EXPERIMENTAL
Intervention: Tasks with varying social and motor engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 0
Study: 31593070

Group type: EXPERIMENTAL
Intervention: Nasal High Flow (NHF) therapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy (COT)
Number of subjects: 400
Study: 28917545

Group type: EXPERIMENTAL
Intervention: Acarbose (50 mg three times a day)
Number of subjects: 6522
Study: 26350812

Group type: EXPERIMENTAL
Intervention: Salsalate 3.5 g/d
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 23083494

Group type: EXPERIMENTAL
Intervention: Inflated abdominal belt to optimal therapeutic pressures
Number of subjects: 80

Group type: COMPARATOR
Intervention: Minimal, non-therapeutic pressures abdominal belt
Number of subjects: 80
Study: 21839402

Group type: EXPERIMENTAL
Intervention: Ustekinumab (45 mg at Weeks 0 and 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept (50 mg biweekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab vs Etanercept
Number of subjects: 0
Study: 19847865

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study: 16737665

Group type: EXPERIMENTAL
Intervention: Iscador Quercus (IQ)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mistletoe lectin (ML) derived from IQ
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: COMPARATOR
Intervention: IQ depleted of ML
Number of subjects: 43
Study: 15649878

Group type: EXPERIMENTAL
Intervention: Simulated reduced gravity (reduced body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Added weight and mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Added mass alone (simulated reduced gravity + added load)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Force to support body weight
Number of subjects: 0
Study: 11680559

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus group drug counseling
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy plus group drug counseling
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Individual drug counseling plus group drug counseling
Number of subjects: 487

Group type: COMPARATOR
Intervention: Group drug counseling alone
Number of subjects: 487
Study: 9770877

Group type: EXPERIMENTAL
Intervention: Coccinia indica, 500 mg/kg body weight, administered orally for six weeks
Number of subjects: 30
Study: 7819650

Group type: EXPERIMENTAL
Intervention: Lactobacillus preparation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 62

Group type: COMPARATOR
Intervention: Hypertonic tube feeding
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tube feeding
Number of subjects: 62
Study: 3043355

Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg bd)
Number of subjects: 305

Group type: COMPARATOR
Intervention: doxycycline (200 mg once daily)
Number of subjects: 305
Study: 31609637

Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI plus panitumumab
Number of subjects: 96

Group type: COMPARATOR
Intervention: FOLFOXIRI
Number of subjects: 96
Study: 28456387

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study: 26385025

Group type: EXPERIMENTAL
Intervention: One-time cardiovascular prevention consult
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: One-time cardiovascular prevention consult plus behavioral intervention program (telephone-based motivational interviewing and tailored text messages)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 23696599

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (no remote ischemic preconditioning)
Number of subjects: 192
Study: 21446609

Group type: EXPERIMENTAL
Intervention: Culturally tailored breast cancer screening intervention delivered in church settings
Number of subjects: 0
Study: 18849052

Group type: EXPERIMENTAL
Intervention: Breast-feeding during immunization (for infants under 6 months)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: 12% sucrose solution (for children aged 6 to 48 months)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (for children aged 6 to 48 months)
Number of subjects: 243

Group type: COMPARATOR
Intervention: No intervention (control group for children aged 6 to 48 months)
Number of subjects: 243

Group type: COMPARATOR
Intervention: No breast-feeding (control group for infants under 6 months)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Sucrose vs. Lidocaine-prilocaine (for children aged 6 to 48 months)
Number of subjects: 243
Study: 16786183

Group type: EXPERIMENTAL
Intervention: Non-contact tonometry (Reichert AT550)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Applanation tonometry (Goldman)
Number of subjects: 55
Study: 15131545

Group type: EXPERIMENTAL
Intervention: Atorvastatin alone (to reduce LDL cholesterol to < or =80 mg/dL)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Atorvastatin plus antioxidant vitamins C and E (to reduce LDL cholesterol to < or =80 mg/dL)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (diet and low-dose lovastatin to reduce LDL cholesterol to < or =130 mg/dL)
Number of subjects: 300
Study: 11315836

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 23
Study: 9040271

Group type: EXPERIMENTAL
Intervention: Combined physical therapy (twice a week for 60 minutes with a therapist, daily unsupervised exercise for 15 minutes)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined physical therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 24
Study: 8187304

Group type: EXPERIMENTAL
Intervention: rhGH (Humatrope, Eli Lilly) 0.5 U/kg/week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3116238

Group type: EXPERIMENTAL
Intervention: Group I received a nutrient solution providing 10 grams of nitrogen as Perifusin and 1400 calories as dextrose and Intralipid with an osmolality of 490 mosmol/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group II received only 15 grams of nitrogen per day as Perifusin with an osmolality of 376 mosmol/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group II
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 30907987

Group type: EXPERIMENTAL
Intervention: Levothyroxine (50 μg once daily)
Number of subjects: 952

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 952
Study: 28077730

Group type: EXPERIMENTAL
Intervention: 2 doses of measles vaccine (MV) at 18 weeks and 9 months
Number of subjects: 1592

Group type: COMPARATOR
Intervention: 1 dose of measles vaccine (MV) at age 9 months
Number of subjects: 1592
Study: 26055400

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 23419384

Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (GHT) with supportive talks and medical treatment (SMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supportive talks with medical treatment (SMT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GHT with SMT
Number of subjects: 100
Study: 21393467

Group type: EXPERIMENTAL
Intervention: Pre-programmed response
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Direct optimization
Number of subjects: 7
Study: 19274363

Group type: EXPERIMENTAL
Intervention: WHO Child Growth Standards
Number of subjects: 806

Group type: COMPARATOR
Intervention: IAP growth curves
Number of subjects: 806
Study: 17867402

Group type: EXPERIMENTAL
Intervention: Novel infant tooth wipe (Spiffies)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Manual toothbrush (Ultra Kids)
Number of subjects: 35
Study: 14758818

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (809 nm‐GaAlAs‐laser, 50 mW, 150 s)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo treatment (simulated laser treatment)
Number of subjects: 52
Study: 11355044

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with conjugated estrogens (0.625 mg/day) and medroxyprogesterone (2.5 mg/day) for 12 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 70
Study: 9207871

Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine (400 mg orally, 90 min before surgery, 2 h after surgery, then every 8 h for 32 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (doubled blind, same timing as ibuprofen-arginine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ibuprofen-arginine and Placebo
Number of subjects: 30
Study: 7953427

Group type: EXPERIMENTAL
Intervention: 0.2 per cent glyceryl trinitrate ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 30
Study: 3591249

Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg of 0.5% bupivacaine injected for the block (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.25% bupivacaine 0.25 mg/kg/h infusion (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg of 0.5% bupivacaine (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine plasma concentration (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine plasma concentration (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine plasma levels (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine plasma levels (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Local anaesthetic effects
Number of subjects: 40
Study: 28287913

Group type: EXPERIMENTAL
Intervention: Skill-based bibliotherapy intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo pill intervention
Number of subjects: 45
Study: 26915375

Group type: EXPERIMENTAL
Intervention: Late Sodium Current Inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24233772

Group type: EXPERIMENTAL
Intervention: Standard triple anti‐H. pylori therapy plus probiotics of L. acidophilus and B. bifidum for 2 weeks followed by taking probiotics for another 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard triple anti‐H. pylori therapy for 6 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standard triple anti‐H. pylori therapy plus probiotics of L. acidophilus and B. bifidum
Number of subjects: 100
Study: 23285445

Group type: EXPERIMENTAL
Intervention: Silver nitrate cautery
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 94
Study: 20339787

Group type: EXPERIMENTAL
Intervention: Topical heparin treatment (group TH)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional treatment (group C)
Number of subjects: 58
Study: 17899018

Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 mg oxycodone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30 mg morphine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 60 mg morphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16087981

Group type: EXPERIMENTAL
Intervention: Valine intake of 17 mg x kg(‐1) x d(‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Valine intakes of 5, 10, 15, 20, 25, 30, and 35 mg x kg(‐1) x d(‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Leucine intake maintained at 40 mg x kg(‐1) x d(‐1)
Number of subjects: 18
Study: 12098023

Group type: EXPERIMENTAL
Intervention: Robot-assisted camera control (RACC) using the AESOP 2000 system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Human camera control
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Robot-assisted camera control (RACC)
Number of subjects: 20
Study: 10332195

Group type: EXPERIMENTAL
Intervention: Combination of adriamycin (ADM) + vincristine (VCR) + cyclophosphamide (CPM) + mitoxantrone + L-asparaginase
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ADM + VCR + PSL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VCR + PSL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Attenuated induction therapy for patients aged 75 or over
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard induction therapy for patients aged less than 75
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 20
Study: 8942334

Group type: COMPARATOR
Intervention: Saline (5 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.75 mg kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (0.24 mg kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.05 mg kg‐1)
Number of subjects: 0
Study: 1574284

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1%
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 92
Study: 3936186

Group type: EXPERIMENTAL
Intervention: Generous insurance plans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-sharing for drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dayton, Ohio site
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insurance plan
Number of subjects: 0
Study: 31244668

Group type: EXPERIMENTAL
Intervention: BFR resistance training (30‐40% 1RM unilateral knee extension) for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual exercise routine
Number of subjects: 24
Study: 28724636

Group type: EXPERIMENTAL
Intervention: Ranibizumab therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 0
Study: 25222757

Group type: EXPERIMENTAL
Intervention: High insulin with essential amino acids (EAAs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low insulin with EAAs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low insulin
Number of subjects: 30

Group type: COMPARATOR
Intervention: High insulin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EAA infusion
Number of subjects: 30
Study: 23229963

Group type: EXPERIMENTAL
Intervention: Focus on Medicines (FOM) program
Number of subjects: 128
Study: 21149757

Group type: EXPERIMENTAL
Intervention: Levothyroxine taken at bedtime
Number of subjects: 105
Study: 17662105

Group type: EXPERIMENTAL
Intervention: Training (T) - 6-month, part-time, mixed-methods training course provided by the Royal College of General Practitioners
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Training (T)
Number of subjects: 112
Study: 15857930

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy, administered as three monthly infusions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (control group of sIBM patients who did not improve).
Number of subjects: 0
Study: 11986599

Group type: EXPERIMENTAL
Intervention: C-MVR (complete chordal preservation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: P-MVR (partial chordal preservation)
Number of subjects: 36
Study: 11490530

Group type: EXPERIMENTAL
Intervention: 32P alone
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: 32P followed by low-dose hydroxyurea (HU) maintenance therapy
Number of subjects: 483
Study: 8017870

Group type: COMPARATOR
Intervention: 4-aminopyridine (AP), oral treatment for 3 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: 3,4 diaminopyridine (DAP), open-label trial
Number of subjects: 68

Group type: COMPARATOR
Intervention: 3,4 diaminopyridine (DAP), double-blind placebo-controlled trial
Number of subjects: 68

Group type: COMPARATOR
Intervention: Crossover comparison of AP and DAP
Number of subjects: 68
Study: 2849011

Group type: EXPERIMENTAL
Intervention: Angiotensin II (7 ng/kg/min)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vasopressin (1 ng/kg/min)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Desmopressin (1 ng/kg/min)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combination of Angiotensin II and Vasopressin with CRF41 (100 micrograms)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Desmopressin with CRF41 (100 micrograms)
Number of subjects: 3
Study: 31742782

Group type: EXPERIMENTAL
Intervention: Storage mite sensitization
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) sensitization
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Co-sensitization to HDM among storage mite sensitized individuals
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Respiratory symptoms and asthma
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Demographic factors (age, education, pet keeping, place of upbringing)
Number of subjects: 1180
Study: 29439943

Group type: EXPERIMENTAL
Intervention: Interactive multimedia (IM) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Microsoft PowerPoint show (PPS) group
Number of subjects: 60
Study: 27825724

Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Imagery rescripting
Number of subjects: 180

Group type: COMPARATOR
Intervention: Moderated self-help group
Number of subjects: 180
Study: 26529074

Group type: EXPERIMENTAL
Intervention: Self-administered intradermal influenza vaccine (Intanza(®))
Number of subjects: 810

Group type: COMPARATOR
Intervention: Nurse-administered intramuscular vaccine (Vaxigrip(®))
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Nurse-led group sessions for self-administration
Number of subjects: 810
Study: 23789889

Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin-pump therapy with threshold-suspend feature
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group (standard sensor-augmented insulin-pump therapy)
Number of subjects: 247
Study: 21552138

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri 1×10 colony-forming units twice daily for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 18513270

Group type: EXPERIMENTAL
Intervention: Pediatric variable stiffness colonoscope (PVSC)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Nonmagnifying adult variable stiffness colonoscope (AVSC)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Magnifying variable stiffness colonoscope (MVSC)
Number of subjects: 216